You are here: Industry Insights > Hemophilia

News List

ISTH Announces Launch Of New Global Education Initiative In Gene Therapy For Hemophilia prnasia
July 08, 2019
The International Society on Thrombosis and Haemostasis (ISTH) is pleased to announce the official launch of Gene Therapy in Hemophilia: An ISTH Education Initiative.
Sangamo, Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy americanpharmaceuticalreview
April 11, 2019
Sangamo, Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy.
Novo Nordisk nabs FDA nod for hemophilia A drug Esperoct but can’t launch until 2020 fiercepharma
February 24, 2019
Novo Nordisk just added a new therapy to its declining hemophilia stable, but it won’t be able to reap the benefit until 2020.
Takeda ex-chairman speaks out against Shire buy a week before key votes fiercepharma
December 06, 2018
Just a week ahead of the final shareholder votes on Takeda’s $62 billion acquisition of Shire, a former Takeda chairman and the last member of the founding family to have run the Japanese pharma has come forward against the deal.
Spark slides on hemophilia A data, aims for phase 3 fiercebiotech
August 08, 2018
Spark Therapeutics’ hemophilia A gene therapy reduced bleeding by 97% in a phase 1/2 trial, building on data reported in December that suggested it may not be as potent as a rival in development at BioMarin.
Pfizer initiates pivotal Phase 3 program for investigational hemophilia B gene therapy worldpharmanews
July 19, 2018
The interventional portion of this pivotal Phase 3 study will enroll patients who have completed at least six months in the lead-in study.
Bioverativ Highlights the Impact of Humanitarian Aid in Hemophilia biospace
April 18, 2018
Bioverativ Inc., a Sanofi company dedicated to transforming the lives of people with rare blood disorders, joins the global hemophilia community in recognizing World Hemophilia Day 2018.
FDA Grants Genentech’s Hemophilia Drug Breakthrough Therapy Designation Despite Reports of Patient Deaths biospace
April 18, 2018
The U.S. Food and Drug Administration (FDA) granted Genentech, a Roche company, Breakthrough Therapy Designation for Hemlibra (emicizumab-kxwh) for hemophilia A without factor VIII inhibitors.
Sanofi Gains Rights to Hemophilia Drug in Restructured Deal With Alnylam biospace
January 09, 2018
Alnylam the leading RNAi therapeutics company, and Sanofi announced today a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development and commercialization of certain products for the treatment of rare genetic dis
Catalyst Biosciences Initiates Phase II/III Trial of Marzeptacog Alfa (activated) for Prophylaxis in biospace
January 05, 2018
Catalyst Biosciences, Inc. Today announced the start of and the second phase of the Phase II Phase 2 plan marzeptacog alfa (MarzAA) is a potent factor VIIa subcutaneously administered for type A or B hemophilia prophylaxis.

Previous page 1 2 3 Next page